Table 1 Correlation between serum exosomal miR-184 expression levels in patients with NSCLC and their clinicopathological characteristics. (* p < 0.05)
From: Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
| Clinicopathological parameters | Number of patients(%) | Exosomal miR-184 | ||
|---|---|---|---|---|
| Low | High | P | ||
| Age(years), Median | 0.777 | |||
| < 60 | 33 | 15 | 18 | |
| ≥ 60 | 31 | 13 | 18 | |
| Gender | 0.899 | |||
| Male | 28 | 12 | 16 | |
| Female | 36 | 16 | 20 | |
| Smoking history | 0.353 | |||
| Never smoking | 49 | 23 | 26 | |
| Now/once smoking | 15 | 5 | 10 | |
| ECOG Score | 0.226 | |||
| 0–1 | 53 | 25 | 28 | |
| ≥ 2 | 11 | 3 | 8 | |
| Primary tumor | 0.705 | |||
| ≤ 4 cm | 19 | 9 | 10 | |
| > 4 cm | 45 | 19 | 26 | |
| TNM | 0.317 | |||
| I–IVA | 25 | 9 | 16 | |
| IVB | 39 | 19 | 20 | |
| PLT | 0.411 | |||
| Low(≤ 146) | 13 | 7 | 6 | |
| High(> 146) | 51 | 21 | 30 | |
| LDH | 0.018* | |||
| Low(≤ 199) | 29 | 8 | 21 | |
| High(> 199) | 35 | 20 | 15 | |
| CEA | 0.129 | |||
| Low(≤ 8.605) | 25 | 8 | 17 | |
| High(> 8.605) | 39 | 20 | 19 | |
| Distant metastasis | 0.164 | |||
| No | 17 | 5 | 12 | |
| Yes | 47 | 23 | 24 | |
| Contralateral lung metastasis | 0.069 | |||
| No | 24 | 7 | 17 | |
| Yes | 40 | 21 | 19 | |
| Pleura metastasis | 0.825 | |||
| No | 33 | 14 | 19 | |
| Yes | 31 | 14 | 17 | |
| Bone metastasis | ||||
| No | 23 | 9 | 14 | |
| Yes | 41 | 19 | 22 | |
| Brain metastasis | ||||
| No | 36 | 14 | 22 | |
| Yes | 28 | 14 | 14 | |